Drug Profile
PSC 100
Alternative Names: HPDSC; Human placenta-derived stem cells; Placental-derived stem cell therapy - Celularity; PSC-100; UCB + HPDSC; UCB and HPDSCLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation; Human Longevity
- Developer Celgene Corporation; Celularity; Human Longevity; New York Medical College
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haematological disorders; Haematological malignancies
- Preclinical Epidermolysis bullosa; Inflammation
- Research Muscular atrophy
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 24 Jul 2018 Phase I development in Haematological malignancies and Haematological disorders is ongoing in USA (IV) (Celularity pipeline, July 2018)
- 01 May 2018 Preclinical trials in Epidermolysis bullosa in USA (unspecified route), before May 2018